WuXi PharmaTech (pronounced woo-shee pharma-tek) is a leading global contract R&D services provider serving the pharmaceutical, biotech, and medical device industries. The company is headquartered in Shanghai and has operations in both China and the United States. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the R&D process. Our services are designed to help our global partners shorten the time and lower the cost of R&D. The parent company is known as WuXi PharmaTech, and its operating divisions are known as WuXi AppTec (pronounced woo-shee app-tek)... More >>
SHANGHAI, March 27, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that an Investigational New Drug (IND) application for WuXi MedImmune's novel anti-IL6 monoclonal antibody for rheumatoid arthritis has been accepted for review by the China Food and Drug Administration (CFDA).
In September 2012, MedImmune, t...
Clinicians, researchers and population genomics programs around the world can build on this unique national effort to use the genome to better prevent, diagnose and treat disease
SHANGHAI, CAMBRIDGE, Massachusetts, and REYKJAVIK, 25 March 2015 – WuXi NextCODE, which provides comprehensive capabilities for using the genome to create better medicine, today congratulated the scientists at deCODE genetics on their publication of the largest studies of whole-genome data yet undertaken.
The studies ...
SHANGHAI, March 12, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, announced today that it will soon begin construction of a new, 145,000-square-foot cGMP facility in Philadelphia for the manufacture of cell therapy products. This facility is designed for cell therapy products that contain viral vectors such as chimeric antigen recepto...
SHANGHAI, March 5, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the fourth quarter and full year of 2014.
Fourth-Quarter 2014 Highlights
Net Revenues Increased 21.3% Year Over Year to $190.6 Million
Laboratory Services Net Revenues Gr...
Sign up to receive e-mail alerts whenever WuXi PharmaTech (Cayman) Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.